日本慢性髓性白血病和多发性骨髓瘤治疗费用与推荐、拒绝、中断关系调查

数据集获取（Figshare）

• 源站标题：The relationship between cost and the recommendation, refusal, and discontinuation of treatment for chronic myeloid leukemia and multiple myeloma in Japan: a cross-sectional exploratory survey
• DOI：10.6084/m9.figshare.19581643.v1
• 发布日期：2022-04-12
• 文件数：2 个
• 文件总体积：964.68 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/The_relationship_between_cost_and_the_recommendation_refusal_and_discontinuation_of_treatment_for_chronic_myeloid_leukemia_and_multiple_myeloma_in_Japan_a_cross-sectional_exploratory_survey/19581643

命令行下载

curl -L -o "ijme_a_2062951_sm0903.pdf" "https://ndownloader.figshare.com/files/34784740"
curl -L -o "ijme_a_2062951_sm0894.docx" "https://ndownloader.figshare.com/files/34784743"

文件清单

• ijme_a_2062951_sm0903.pdf（906.05 KB）
• ijme_a_2062951_sm0894.docx（58.63 KB）

文件总体积 964.68 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

This study aimed to ascertain the number of patients with chronic myelogenous leukemia (CML) and transplant-ineligible patients with multiple myeloma (MM) not recommended by their physicians for optimal drug treatment or who refuse, discontinue, reduce, or skip treatment owing to cost in Japan.
A cross-sectional survey was conducted among hematologists, hematologic oncologists, and oncologists in Japan treating ≥1 patient with CML or ≥5 transplant-ineligible patients with MM per year.
A total of 212 physicians participated: 105 treating patients with CML and 107 treating transplant-ineligible patients with MM. While treatment cost did not lead to non-optimal treatment most patients, physicians reported that they recommended non-optimal treatment to 6.53% of their patients with CML and 1.41% of their transplant-ineligible patients with MM, that 1.51 and 0.35% of their patients, respectively, refused treatment and that 1.97 and 0.71% discontinued treatment owing to treatment cost. However, no significant differences in the effect of treatment cost on recommendation, discontinuation, refusal, or reduction of treatment were observed. Non-recommendation of optimal treatment owing to treatment cost was most common for third-line CML and fourth-line transplant-ineligible MM treatment. Discontinuation due to treatment cost was most common in third-line treatment for both.
Our results show that non-optimal treatment due to treatment cost occurs among some physicians in Japan for patients with CML and transplant-ineligible patients with MM, but it may be limited to a small percentage of patients. Further research is needed to identify the drivers of treatment decisions for physicians and patients, including those involving treatment cost.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.19581643.v1（source: https://tandf.figshare.com/articles/dataset/The_relationship_between_cost_and_the_recommendation_refusal_and_discontinuation_of_treatment_for_chronic_myeloid_leukemia_and_multiple_myeloma_in_Japan_a_cross-sectional_exploratory_survey/19581643）。